Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis. (31st December 2022)

• Record Type: Journal Article
• Authors: Gallagher, Meghan E.; Chawla, Anjulika; Brady, Brenna L.; Badawy, Sherif M.
• Is Part Of: Journal of medical economics. Volume 25:Number 1(2022)
• Page Start: 1140
• Page End: 1148
• Publication Date: 2022-12-31
• Subjects: Sickle cell -- economics -- burden of illness -- healthcare resource utilization -- lifetime costs -- medical decision making; I10 -- I1 -- I -- I11 -- I12 -- I18; Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.1080/13696998.2022.2133824
• Languages: English
• ISSNs: 1369-6998

Abstract

Abstract: Background: Sickle cell disease (SCD) is a lifelong burdensome disorder of heterogenic expression. This study investigated the longer-term economic burden of severe presentation of SCD. As SCD treatment landscapes evolve toward curative intent gene therapies, understanding how SCD-associated costs may change over the patient lifetime will be important for medical decision-making. Methods: Patients with severe presentation of SCD (presence of acute vaso-occlusive events [VOEs] or history of stroke and/or other disease-related sequelae), were identified within the MarketScan Commercial and Medicare Supplemental and Multi-state Medicaid Databases from 1/1/2010 to 12/31/2018. The first SCD claim served as the index date and patients were followed over a 5-year post-period. Clinical characteristics and healthcare resource utilization and costs were assessed over follow-up for eligible cohorts of commercial and Medicaid patients with severe SCD presentation and age-based subgroups (<18, 18–30, and ≥31). Results: A total of 4, 487 patients, primarily insured via Medicaid (79.2%), qualified for the analysis. Patients evidenced persistent VOEs over follow-up; prevalence of most comorbidities increased with age. Mean total healthcare costs over the 5-year follow-up were $275, 143 (SD± $406, 770) and $362, 728 (SD± $620, 189) in the commercial and Medicaid samples, respectively. Disease severity, assessed by the number of VOEs and utilization of inpatient and emergency services, peaked in the 18–30 year group in both samples. These groups also evidenced the highest mean healthcare costs over the 5-year follow-up at $344, 776 (SD± $434, 521) and $671, 321 (SD± $938, 764) in the commercial and Medicaid samples respectively. Conclusion: Results indicate high clinical need and economic burden among patients with severe presentation of SCD. These findings not only highlight the need for improved therapeutic options to limit or prevent disease progression, but also start to provide insight on lifetime costs of SCD that will be needed in the evaluation of emerging curative intent therapies.